Tony W. Ho
2019
In 2019, Tony W. Ho earned a total compensation of $6M as EVP, Research and Development at CRISPR Therapeutics AG, a 45% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $281,603 |
|---|---|
| Option Awards | $1,948,674 |
| Salary | $431,575 |
| Stock Awards | $3,333,900 |
| Other | $9,800 |
| Total | $6,005,552 |
Ho received $3.3M in stock awards, accounting for 56% of the total pay in 2019.
Ho also received $281.6K in non-equity incentive plan, $1.9M in option awards, $431.6K in salary and $9.8K in other compensation.
Rankings
In 2019, Tony W. Ho's compensation ranked 1,701st out of 13,971 executives tracked by ExecPay. In other words, Ho earned more than 87.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,701 out of 13,971 | 88th |
Division Manufacturing | 608 out of 5,695 | 89th |
Major group Chemicals And Allied Products | 183 out of 2,194 | 92nd |
Industry group Drugs | 146 out of 1,880 | 92nd |
Industry Biological Products, Except Diagnostic Substances | 34 out of 389 | 91st |
Source: SEC filing on April 24, 2020.
Ho's colleagues
We found four more compensation records of executives who worked with Tony W. Ho at CRISPR Therapeutics AG in 2019.
News
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2021 pay jumps 87% to $17M
April 25, 2022
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2020 pay falls 44% to $9.1M
April 28, 2021
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2019 pay jumps 67% to $16M
April 24, 2020
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2018 pay jumps 40% to $9.7M
April 30, 2019